Tesamorelin (20mg)

GHRH Analog (Extended Research Protocol Vial)

Tesamorelin (20mg) will be supplied in Australia by Aussie Peptides with fast domestic shipping to all states and territories.

Tesamorelin is a stabilised analog of growth hormone-releasing hormone (GHRH). It is studied for body recomposition research — specifically the preferential reduction of visceral adipose tissue (VAT) rather than general weight change. Mechanism: stimulated endogenous GH release with downstream IGF-1 elevation. This distinguishes Tesamorelin from GLP-1-class compounds, which act via appetite and gastric emptying.

The 20mg format suits extended research protocols.

Key Research Areas

• Visceral Adipose Reduction — Studied specifically for reducing deep visceral abdominal fat
• Body Recomposition — Research focused on fat distribution rather than gross bodyweight change
• GH/IGF-1 Axis — Stimulates endogenous GH release; studied for IGF-1-mediated downstream effects
• Recovery Research — GH/IGF-1 effects studied in tissue repair and conditioning models
• Extended-Protocol Format — 20mg vial suitable for longer research protocols

Supplied as lyophilized powder at high purity, verified by HPLC and mass spectrometry. 20mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.